Adenosine Receptors  by Ciruela, Francisco
Biochimica et Biophysica Acta 1808 (2011) 1231–1232
Contents lists available at ScienceDirect
Biochimica et Biophysica Acta
j ourna l homepage: www.e lsev ie r.com/ locate /bbamemPreface
Adenosine ReceptorsSince Drury and Szent-Györgyi found 80 years ago that adenosine
produced profound hypotension and bradycardia, as well as it affected
kidney function in mammals [1], the physiological roles and potential
therapeutic use of adenosine have been largely considered [2,3].
Adenosine has been mainly thought to be a retaliatory metabolite [4]
that increases oxygen supply and decreases oxygen consumption,
therefore this purine nucleoside can potentially regulate a large
amount of physiological processes (i.e. respiratory regulation,
hormone action, neural function, platelet aggregation, lymphocyte
differentiation and vascular tone). In addition, adenosine exerts a
negative chronotropic and dromotropic effect on the heart, as well as
it mediates the inhibition of neurotransmitters release and lipolysis.
Intriguingly, while adenosine is able to induce the dilation of some
blood vessels (i.e. the coronary arteries) [5] it can produce the reverse
effect in some others (i.e. the small renal blood vessels) [6], thus
resulting in opposite physiological effects (i.e. vasodilatation vs.
vasoconstriction, respectively). Overall, it has been assumed that this
purine nucleoside is a mediator of metabolic distress, thus having
considerable impact on homeostatic cellular functioning.
In 1972 it was shown that adenosinewas released from brain slices
upon electrical stimulation [7]. Interestingly, the released adenosine
produced an increase in the intracellular levels of cAMP, an effect that
was antagonized by methylxanthines such as caffeine and theophyl-
line [8], a fact that was also observed in the heart [9]. Collectively,
these observations constituted the ﬁrst evidence suggesting that
adenosine exerted its effects via speciﬁc plasma membrane receptors.
Afterwards, it was demonstrated that the so described antilipolytic
effect of adenosine on fat cells occurred with a concomitant reduction
in cAMP [10]. The dual effects of adenosine on cAMP formation were
further substantiated when it was demonstrated that adenosine could
either inhibit or stimulate adenylyl cyclase. Overall, these observa-
tions ended with the ﬁrst subclassiﬁcation of adenosine receptors into
Ri and Ra [11], or alternatively, A1 and A2 adenosine receptors [11].
Hence, it was assumed that adenosine exerted its actions through G
protein-coupled adenosine receptors, which in turn were expressed
in a large variety of cells and tissues. For instance, in the Central
Nervous System (CNS) adenosine has been shown to play a key
regulatory role, acting as a presynaptic, postsynaptic and/or non-
synaptic neuromodulator [12]. Extracellular adenosine in the brain is
related to the intracellular concentration of adenosine and nucleo-
tides, such as ATP, AMP and cAMP [13]. In some brain areas, like the
hippocampus, most of the extracellular adenosine seems to depend
mostly on intracellular adenosine, the concentration of which is
related to the rate of breakdown and synthesis of ATP [13]. Thus,
adenosine is released as a neuromodulator [14] by the effector cells in
response to an increased metabolic demand [15]. However, in the
striatum, it has been suggested that the main source of extracellular0005-2736/$ – see front matter © 2011 Published by Elsevier B.V.
doi:10.1016/j.bbamem.2011.03.007adenosine is the intracellular cAMP [16]. Since cAMP can only be
generated by the action of the enzyme adenylyl cyclase, striatal
extracellular adenosine would mostly reﬂect an increased activation
of receptors positively linked to adenylyl cyclase.
Four subtypes of adenosine receptors (ARs) have been identiﬁed
so far, namely A1R, A2AR, A2BR and A3R. These receptors have a
distinctive pharmacological proﬁle, tissue distribution and effector
coupling [17]. ARs belong to the rhodopsin family of G protein-
coupled receptors (GPCRs), also called family I or A [18]. This receptor
family has more than 700 different members that share some
phylogenetic and intrinsic characteristics. For instance, within their
sequence all adenosine receptors contain thewidely conserved NPxxY
(x)5,6F and the DRY motifs [19,20]. Thus, adenosine-mediated
conformational change in the ARs core domain affects the conforma-
tion of the intracellular loops, which in turns determines the binding
and activation of speciﬁc G proteins responsible for the activation of
different intracellular signaling pathways associated to adenosine
function.
The present issue of Biochimica et Biophysica Acta—Biomembranes
is designed to summarize the main aspects of the state of the art of
ARs. Thus, using ARs as a paradigm of GPCRs it is intended to provide
to the reader a clear picture of how these receptors, by interacting
with their surrounding milieu, mediate adenosine function. Accord-
ingly, the issue is structured in four sections. The ﬁrst section focuses
in the structure-function relationships of these receptors, thus, the
recent structural features and oligomerization abilities of adenosine
receptors are analyzed. The second section analyzes the medicinal
chemistry surrounding these receptors, thus the recent developments
in adenosine receptors ligands and allosteric modulators are de-
scribed. In the third section the signaling aspects of these receptors
are analyzed. The last section compiles the most remarkable
pathological and therapeutic aspects related to adenosine receptors.
Overall, I hope that this timely focused issue summarizing our current
knowledge on adenosine receptors will be of interest to a wide range
of readers of the journal interested in the purinergic ﬁeld.
Finally, I wish to express my best thanks to all authors and co-
authors of the issue for their commitment and to the anonymous
reviewers for their excellent contributions. In addition, I want to
express my special gratitude to the Executive Editors of BBA-
Biomembranes and to the staff at Elsevier/BBA for their assistance.
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